Nebulized Bronchodilators and Cardiac Repolarization

• Status: Completed
• Trial end date: 2013-12-31
• Target enrollment: 0
• Participant gender: All

Summary

Patients of the ICU's often require bronchodilatory treatment due to bronchospasm caused by conditions like : acute respiratory distress syndrome (ARDS), chronic obstructive pulmonary disease (COPD) or asthma. The β2 adrenergic drugs are one of the most commonly used for this purpose. However it is known that they may cause tachycardia and may have substantial proarrhythmic effect. The investigators' aim is to estimate the influence of nebulized bronchodilatory drugs on selected electrophysiological parameters, whose changes are generally recognized as potentially increasing the risk of ventricular and supraventricular arrhythmias. Two drugs will be compared - salbutamol given in two doses and ipratropium bromide

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Medical University of Gdansk
• Treatments: Albuterol; Ipratropium

Criteria

Inclusion Criteria:

• the necessity of b2 adrenergics an m2 mimetics administration

Exclusion Criteria:

• patients with past medical history of ventricular arrhythmias ( ventricular tachycardia, ventricular fibril, Torsade de pointes)

• patients with persistent atrial fibrillation

• patients with abnormal plasma sodium, potassium, magnesium, and ionized calcium concentration